Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Clinical trial NCT03341936 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03341936
Sponsor: Dana-Farber Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Squamous Cell Carcinoma of the Head and Neck

Start date: 2018-03-15
Primary completion: 2021-07-06
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.